5th World ADC Summit South Korea

The 5th World ADC Summit South Korea (9-11 June 2026 | Seoul) is Asia's premier meeting dedicated to accelerating next-generation antibody drug conjugate (ADC) development. As part of the broader World Targeted Therapeutics Summit South Korea, it sits alongside the World TPD and Induced Proximity Summit South Korea and the World Bispecifics and T-Cell Engager Summit South Korea, creating a unified hub for cutting-edge targeted therapeutics innovation.
 
The event brings together more than 300 experts from Korean and global biopharma to address the country's rapid shift from biosimilars toward high-value, first- and best-in-class ADCs. With novel payloads, dual-payload platforms, bispecific ADCs, and strategies to overcome Topo-1 resistance at the forefront, the summit provides end-to-end insights across discovery, preclinical and clinical development, and CMC. Attendees gain access to three dedicated ADC content tracks, two pre-conference days, and additional sessions on bispecifics, T-cell engagers, and targeted protein degradation.
 
Featuring 35+ speakers from organizations such as Daiichi Sankyo, Astellas, Pfizer, AbbVie, and Kanaph Therapeutics, the summit offers unmatched opportunities for scientific exchange, partnership building, and technology showcasing. As part of the co-located World Targeted Therapeutics Summit, it plays a central role in establishing South Korea as a rising global hub for precision-driven cancer therapeutics.